Walgreens Boots Alliance has agreed to pay $106.8M to resolve alleged violations of the False Claims Act and state statutes for billing government health care programs for prescriptions never dispensed, the Department Justice said in a statement. The government alleges that, between 2009 and 2020, Walgreens submitted false claims for payment to Medicare, Medicaid and other federal health care programs for prescriptions that it processed but that were never picked up by beneficiaries. As part of the resolution, Walgreens received credit under the department’s guidelines for taking disclosure, cooperation and remediation into account in False Claims Act cases. Among other actions, Walgreens implemented enhancements to its electronic pharmacy management system to prevent this from occurring in the future and self-reported certain conduct.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WBA:
- Walgreens Boots Alliance price target lowered to $16 from $22 at TD Cowen
- Walgreens Stock (WBA) Plummets to a Multi-Decade Low, Leaving Investors Wondering
- Walgreens Boots Alliance price target lowered to $7.50 from $11 at BofA
- Walgreens Boots Alliance price target lowered to $15 from $20 at JPMorgan
- Bilt Rewards enters strategic collaboration with Walgreens Boots Alliance